| 引用本文: | 袁倩,肖健豪,李晓东,胡圣文,王运良.米氮平与舍曲林治疗帕金森病抑郁的临床效果比较[J].中国临床新医学,0,():-. |
| yuanqian.米氮平与舍曲林治疗帕金森病抑郁的临床效果比较[J].中国临床新医学,0,():-. |
|
| 摘要: |
| 目的 探讨米氮平治疗帕金森病抑郁的有效性和安全性。方法 选取2015-01～2018-01在武汉红桥脑科医院神经内科确诊为帕金森病抑郁的患者96例进行回顾性研究。分为对照组和观察组，每组48例，对照组给予舍曲林治疗，观察组给予米氮平治疗，治疗时间均为12周，记录两组患者治疗前后汉密尔顿抑郁量表（Hamilton DePression Scale，HAMD）评分、日常生活能力量表（Activity of Daily Living Scale，ADL）评分、匹兹堡睡眠质量指数（Pittsburgh Sleep Quality Index，PSQI）评分及治疗期间的不良反应发生情况。结果 治疗前，两组的年龄、性别、帕金森病程、帕金森抑郁病程、HAMD、ADL、PSQI评分均无统计学意义（P＞0.05）。治疗12周后，两组HAMD、PSQI评分均降低，ADL评分均升高，观察组HAMD、ADL、PSQI评分分别为（8.02±3.43、61.29±9.22 、4.88±1.94），对照组评分为（12.46±3.34、7.50±2.27和55.08±10.84），治疗后两组各项评分差异均具有统计学意义(P＜0.05)。副作用比较，观察组在胃肠道反应方面比对照组少，差异有统计学意义(P＜0.05)。结论 帕金森病抑郁选择药物治疗时，米氮平有较好的抗抑郁作用，且不良反应较舍曲林少，可作为帕金森病抑郁治疗的选择之一。 |
| 关键词: 帕金森病 抑郁症 米氮平 舍曲林 |
| DOI： |
| 分类号: |
| 基金项目: |
|
| The Comparison of clinical effects of mirtazapine and sertraline in the treatment of Parkinson's disease with depression |
|
yuanqian
|
|
The Second Affiliated Hospital of Zhengzhou University
|
| Abstract: |
| Objective: To investigate the efficacy and safety of mirtazapine treatment for parkinson's depression. Methods: A retrospective study was performed on 96 patients diagnosed with Parkinson's depression in the Department of Neurology, Wuhan Hongqiao Brain Hospital from January 2015 to January 2018. They were divided into control group and observation group, each group were 48 patients,the control group was treated with sertraline, and the observation group was treated with mirtazapine. The treatment time were both 12 weeks,the Hamilton Depression Scale(HAMD)score, Activity of Daily Living Scale(ADL) score, Pittsburgh Sleep Quality Index(PSQI) score, and adverse events during treatment were recorded adverse reactions during treatment in both groups. Results: Before treatment, there were no significant difference in age、Parkinson's disease course、 Parkinson's depression course 、and the scores of HAMD、ADL and PSQI between the two groups (P＞0.05). After 12 weeks of treatment, the HAMD and PSQI scores of both groups decreased, and the ADL scores increased,the HAMD, ADL and PSQI scores of the observation group were(8.02±3.430, 61.29±9.221, 4.88±1.942), and the control group scored (12.46±3.339, 7.50±2.269, 55.08±10.841). The differences in scores between the two groups after treatment were statistically significant. (P<0.05).Compared with side effects, The observation group had fewer gastrointestinal reactions than the control group, and the difference was statistically significant (P＜0.05). Conclusion: When Parkinson's depression is given medication, mirtazapine has a better antidepressant effect than sertraline, and the adverse reaction is less than sertraline, which can be used as one of the choices for Parkinson's depression treatment. |
| Key words: Parkinson's disease depression mirtazapine sertraline |
